SAN CARLOS, Calif., May 22 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will host its first research and development briefing for analysts and investors on Friday, June 16, 2006, from 9:30 a.m.-12:30 p.m. Eastern Time. To access the live audio broadcast or the subsequent archived recording log on to http://www.nuvelo.com.
Nuvelo's management and scientists will review the company's clinical development of acute cardiovascular and cancer therapies. Speakers, including Randall T. Higashida, M.D., of the University of California at San Francisco Medical Center, will discuss the clinical issues and current treatments for stroke and DVT and the role alfimeprase can play in these indications. Speakers will also address Nuvelo's emerging oncology pipeline including NU206 and rNAPc2. Company spokespeople will include Ted Love, M.D., Chairman and Chief Executive Officer; Michael Levy, M.D., Sr. Vice President Research and Development; Steven Deitcher, M.D., Vice President Medical Sciences; Walter Funk, Ph.D., Vice President Research; and Jim Buchanan, Sr. Director Drug Safety.
INVITED ACADEMIC CLINICAL EXPERT
STROKE: CLINICAL PROBLEM AND GOALS OF THERAPY Randall T. Higashida, M.D.
Dr. Higashida is Clinical Professor of Radiology, Neurological Surgery, Neurology, and Anesthesiology at the University of California at San Francisco Medical Center. He is Chief of the Division of Interventional Neurovascular Radiology at UCSF Medical Center, one of the leading institutions specializing in the minimally invasive treatment of complex cerebrovascular diseases and stroke.
Dr. Higashida has published over 220 scientific articles on stroke and related topics and authored over 100 book chapters. His articles have appeared in Stroke, American Journal of Neuroradiology, Journal of Neurosurgery, Journal of Endovascular Surgery, Lancet, Neurology, and the Journal of the American Medical Association. He is on ten scientific editorial boards and serves as a manuscript reviewer for seven additional journals.
As a leader on interventional neuroradiology procedures and stroke, Dr. Higashida has presented at over 550 scientific and professional meetings around the world.
Dr. Higashida is a member of numerous medical and scientific committees including the Cerebrovascular Neurosurgery Task Force Committee, the American Heart Association Stroke Council Research Committee, the American Society of Neuroradiology Executive Committee, and the American Society of Interventional and Therapeutic Neuroradiology Executive Committee. He is the past President of the American Society of Interventional and Therapeutic Neuroradiology, chairman of the American Heart Association Committee on Cerebrovascular Imaging, a consulting member of the U.S. FDA Neurological Devices Panel, and on the oversight committee of the National Institutes of Health for carotid artery stenting.
Dr. Higashida earned his medical degree from the School of Medicine at Tulane University in New Orleans, Louisiana.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in four Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex in Phase 2 clinical development for acute coronary syndromes; and a thrombin inhibiting aptamer for anticoagulation during medical procedures. Nuvelo is also progressing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.CONTACT: Nicole Estrin, Associate Director of Corporate, Communications &IR, +1-650-517-8472, or nestrin@nuvelo.com; or Daryl Messinger of WeissCommPartners, Inc, +1-415-999-2361, or daryl@weisscommpartners.com, for Nuvelo,Inc.
Web site: http://www.nuvelo.com/
